An arrhythmia diagnosis rarely comes with a simple treatment prescription. The treatment that is right for atrial fibrillation is not the same as the one that is right for ventricular tachycardia. The same rhythm disorder that is safely managed with medication in one patient requires catheter ablation in another with the same ECG finding, because the symptom burden, the underlying structural heart disease, and the risk of sudden cardiac death differ.
The decision between medication, catheter ablation, and device therapy is not a hierarchy where one approach supersedes the others it is an individualised clinical selection process driven by the specific arrhythmia, its haemodynamic consequences, the patient's underlying heart disease, and the risk the rhythm poses to life.
For international patients from Nigeria, Bangladesh, Kenya, the UAE, and South Asia, India's electrophysiology centres at NABH and JCI-accredited hospitals offer the full spectrum of arrhythmia management at 60 to 80 percent lower cost than Western equivalents. This guide explains what the treatment options are, when each is appropriate, and how to access the right care in India.
Recognising Arrhythmias Symptoms
Arrhythmias symptoms vary enormously by the type of rhythm disorder, the heart rate it produces, and whether any structural heart disease is present. Not every arrhythmia produces dramatic symptoms.
Symptom Patterns by Arrhythmia Type
Tachyarrhythmias (heart beating too fast) produce:
-
Palpitations — the most consistent symptom, described as a fluttering, racing, or pounding sensation in the chest
-
Lightheadedness or dizziness from reduced cardiac output during rapid heart rates
-
Breathlessness, particularly with exertion or when the arrhythmia begins suddenly
-
Chest discomfort from increased myocardial oxygen demand
-
Presyncope (near-fainting) or syncope (loss of consciousness), particularly with ventricular tachycardia or fast supraventricular tachycardias
Bradyarrhythmias (heart beating too slowly) produce:
-
Fatigue and exercise intolerance
-
Lightheadedness and dizziness, particularly on standing
-
Syncope — which is the most serious bradycardia symptom and mandates urgent assessment
-
Confusion in older patients from reduced cerebral perfusion
Atrial fibrillation specifically produces:
-
Irregular palpitations, often described as chaotic rather than rapid
-
Fatigue and reduced exercise capacity (even in asymptomatic patients, AF impairs cardiac output by removing the atrial contribution to ventricular filling)
-
Stroke symptoms, because AF creates conditions for thrombus formation in the left atrial appendage
When Arrhythmias Symptoms Need Urgent Assessment
The following warrant same-day cardiology or emergency assessment:
-
Syncope or near-syncope during physical activity
-
Syncope with structural heart disease (known cardiomyopathy, prior heart attack, heart failure)
-
Sustained palpitations lasting more than 30 minutes
-
Palpitations accompanied by chest pain, breathlessness, or confusion
-
A known or suspected inherited arrhythmia syndrome (Brugada syndrome, Long QT syndrome, ARVC) with any new symptom
Understanding the Treatment Decision Framework
The decision to treat an arrhythmia depends on its symptoms and its potential severity. Treatment is directed at causes. If necessary, direct antiarrhythmic therapy, including antiarrhythmic drugs, cardioversion-defibrillation, implantable cardioverter-defibrillators (ICDs), pacemakers (and a special form of pacing, cardiac resynchronization therapy), catheter ablation, surgery, or a combination, is used.
This framework from the Merck Manual (February 2025) captures the essential reality: arrhythmia treatment is a multimodal spectrum, not a binary choice. The right treatment or combination is selected based on arrhythmia type, reversibility, haemodynamic impact, underlying cardiac structure, and the risk of life-threatening events.
Treatment Option 1: Antiarrhythmic Medications
Medications are the starting point for most arrhythmias, either as definitive treatment or as a bridge while other therapies are being evaluated or planned.
Rate Control Versus Rhythm Control in Atrial Fibrillation
For atrial fibrillation, the first decision is whether to control the heart rate (rate control) or attempt to restore and maintain sinus rhythm (rhythm control).
-
Rate control uses beta-blockers (metoprolol, bisoprolol), calcium channel blockers (diltiazem, verapamil), or digoxin to keep the ventricular rate below 80 to 100 beats per minute, allowing the heart to function adequately despite the irregular rhythm.
-
Rhythm control uses antiarrhythmic drugs including flecainide, propafenone (for patients without structural heart disease), or amiodarone (for patients with structural heart disease) to maintain sinus rhythm alongside anticoagulation.
The 2020 EAST-AFNET 4 trial established that early rhythm control in AF patients reduces cardiovascular outcomes compared to rate control alone, and this finding has influenced practice toward rhythm control as the preferred initial strategy in most newly diagnosed AF patients.
Antiarrhythmic Drugs for Other Tachyarrhythmias
-
Flecainide and propafenone: pill-in-the-pocket approach for paroxysmal SVT in patients without structural heart disease
-
Sotalol: for ventricular tachycardia and AF in patients with structural heart disease
-
Amiodarone: the most effective antiarrhythmic for suppressing a broad range of tachyarrhythmias, but with significant long-term toxicity to thyroid, lungs, liver, and cornea that limits its use to patients where other agents have failed or are contraindicated
-
Ivabradine: for inappropriate sinus tachycardia
-
Mexiletine: adjunct to amiodarone in refractory ventricular tachycardia
When Medication Is Sufficient
Medication is appropriate as the primary or sole treatment for:
-
Rate control in permanent AF where rhythm control is not sought
-
Asymptomatic or mildly symptomatic arrhythmias where the rhythm is not life-threatening
-
Patients who decline or are not candidates for ablation or device therapy
-
Short-term management while a reversible cause is addressed
Treatment Option 2: Catheter Ablation
Catheter ablation is the definitive treatment for many arrhythmias and, for specific conditions, offers cure rather than ongoing suppression.
How Catheter Ablation Works
A catheter is passed through the femoral vein or artery, navigated under fluoroscopic and electroanatomical mapping guidance to the precise site of the arrhythmia origin or the critical pathway sustaining it. Energy most commonly radiofrequency (RF), delivered at 300 to 750 MHz and producing localised tissue heating is applied to destroy (ablate) the arrhythmogenic tissue or interrupt the reentrant circuit.
Cryotherapy (freezing) is used as an alternative to RF energy in specific anatomical locations, particularly near the atrioventricular node where the risk of inadvertent complete heart block with RF ablation is higher.
Success Rates for Specific Arrhythmias
Ablation achieves different levels of success by arrhythmia type:
-
AVNRT (atrioventricular nodal reentrant tachycardia): The most common regular SVT in adults. Ablation achieves cure in 95 to 98 percent of cases with recurrence rates of only 1 to 2 percent per Max Healthcare India electrophysiology data.
-
WPW syndrome: Ablation of the accessory pathway cures WPW and eliminates the risk of sudden cardiac death from rapid pre-excited AF.
-
Atrial flutter: Cavotricuspid isthmus (CTI) ablation achieves acute success in over 95 percent of typical atrial flutter cases.
-
Atrial fibrillation: Pulmonary vein isolation (PVI) achieves freedom from AF at one year in 60 to 70 percent of paroxysmal AF patients and 50 to 60 percent of persistent AF patients. Repeat ablation improves cumulative outcomes.
-
Ventricular tachycardia: In structurally normal hearts, ablation achieves cure in 80 to 90 percent. In structural heart disease, ablation reduces VT burden and ICD shocks but rarely achieves complete cure.
The 2026 French nationwide registry of 1,135 catheter ablation procedures in CHD patients confirmed acute success in 94.4 percent overall, with freedom from arrhythmia recurrence of 77.3 percent at one year and 68.4 percent at two years. Acute complications occurred in only 3.8 percent of procedures.
Advanced Ablation Technologies in India
India's leading electrophysiology centres use the full range of modern ablation technologies:
-
3D electroanatomical mapping systems (CARTO, EnSite) for real-time cardiac geometry and ablation lesion visualisation
-
Contact force sensing catheters that confirm adequate lesion depth during RF delivery
-
Cryoballoon ablation for pulmonary vein isolation in AF
-
Pulsed field ablation (PFA), the newest ablation energy modality, which selectively destroys cardiac tissue with minimal collateral damage to the oesophagus and phrenic nerve — reducing procedure-specific complications versus RF ablation in AF
When Ablation Is the Right Choice
Ablation is strongly preferred or indicated when:
-
A curable arrhythmia is present (AVNRT, WPW, typical atrial flutter)
-
AF is symptomatic and medication has failed or is not tolerated
-
Ventricular tachycardia occurs in a structurally normal heart
-
The patient is young and wishes to avoid lifelong antiarrhythmic medication
-
Antiarrhythmic medications have failed to suppress an arrhythmia that significantly impairs quality of life
Treatment Option 3: Device Therapy
Device therapy encompasses pacemakers and implantable cardioverter-defibrillators (ICDs), each targeting a different arrhythmia problem.
Permanent Pacemakers
Pacemakers are indicated for symptomatic bradyarrhythmias where the heart rate is insufficiently fast to support adequate cardiac output. Key indications:
-
Sick sinus syndrome causing symptomatic bradycardia or pauses
-
Complete heart block (third-degree AV block) regardless of symptoms
-
High-degree (second-degree Mobitz II) AV block
-
Symptomatic chronotropic incompetence (failure of the heart rate to increase appropriately with exertion)
Modern pacemakers are dual-chamber (sensing and pacing both atrium and ventricle), rate-responsive (accelerating pacing rate with activity), and increasingly leadless (implanted directly into the heart without transvenous leads). His bundle pacing and left bundle branch area pacing preserve the natural ventricular activation sequence and are superior to right ventricular apical pacing in reducing the risk of pacing-induced cardiomyopathy.
Implantable Cardioverter-Defibrillators (ICDs)
ICDs cardiovert or defibrillate the heart in response to ventricular tachycardia (VT) or ventricular fibrillation (VF). They are indicated for:
-
Secondary prevention after survival of sudden cardiac arrest from VT or VF
-
Primary prevention in patients with significantly reduced left ventricular ejection fraction (LVEF below 35 percent) from ischaemic or non-ischaemic cardiomyopathy, who are at high risk of sudden cardiac death
-
Specific inherited arrhythmia syndromes including hypertrophic cardiomyopathy with high-risk features, ARVC, Long QT syndrome with prior cardiac arrest, and Brugada syndrome in high-risk patients
The 2025 meta-analysis comparing catheter ablation versus ICD therapy in symptomatic Brugada syndrome patients confirms that ablation significantly reduces VF recurrence (RR 0.36, 95% CI 0.22 to 0.58) compared to standard ICD-based management, establishing ablation as a complementary rather than exclusive alternative to ICD in this condition.
Cardiac Resynchronisation Therapy (CRT)
CRT is a specialised form of pacing that coordinates the contraction of both ventricles simultaneously in patients with heart failure and left bundle branch block, improving cardiac function and reducing heart failure hospitalisations and mortality.
Choosing Between the Three Approaches in India
The treatment decision for any arrhythmia is not made by the patient alone. It requires an electrophysiologist a cardiologist with specific subspecialty training in cardiac electrophysiology who has reviewed the ECG, Holter monitor data, echocardiogram, and full clinical history.
The decision framework in practice:
| Arrhythmia | First-line approach | When to escalate |
|---|---|---|
| AVNRT / WPW | Ablation (curative) | Not applicable |
| Typical atrial flutter | Ablation (curative) | |
| Paroxysmal AF, symptomatic | Rhythm control drugs or ablation | Ablation after one drug failure |
| Persistent AF | Rate control plus rhythm control drugs | Ablation after drug failure |
| Complete heart block | Permanent pacemaker | Not applicable |
| Sick sinus syndrome | Permanent pacemaker | Not applicable |
| VT in structural heart disease | ICD plus medication; ablation for recurrence reduction | ICD is foundational; ablation adjunctive |
| Post-cardiac arrest VF | ICD (secondary prevention) | Ablation if recurrent VT/VF despite ICD |
Cost of Arrhythmia Treatment in India
| Treatment | India cost | USA / UK equivalent |
|---|---|---|
| Electrophysiology study and ablation (SVT) | Rs. 1,50,000 to Rs. 3,00,000 (USD 1,800 to USD 3,600) | USD 15,000 to USD 40,000 |
| AF ablation (cryoballoon or RF PVI) | Rs. 2,50,000 to Rs. 5,00,000 (USD 3,000 to USD 6,000) | USD 25,000 to USD 60,000 |
| Permanent pacemaker implantation | Rs. 1,20,000 to Rs. 3,00,000 (USD 1,450 to USD 3,600) | USD 15,000 to USD 35,000 |
| ICD implantation | Rs. 3,00,000 to Rs. 6,00,000 (USD 3,600 to USD 7,200) | USD 30,000 to USD 70,000 |
| CRT-D device implantation | Rs. 4,00,000 to Rs. 8,00,000 (USD 4,800 to USD 9,600) | USD 40,000 to USD 80,000 |
| Leadless pacemaker | Rs. 3,50,000 to Rs. 6,00,000 (USD 4,200 to USD 7,200) | USD 30,000 to USD 60,000 |
All represent savings of 60 to 80 percent versus the USA or UK, using the same internationally certified devices from Medtronic, Abbott, Boston Scientific, and Biotronik.
How Karetrip Connects International Patients to India's Electrophysiology Centres
Two patients with palpitations may have completely different arrhythmias requiring completely different treatments. Karetrip reviews each patient's ECG, Holter monitor reports, echocardiogram, and clinical history before recommending an electrophysiology centre in India, confirming that the proposed centre has the specific ablation technology and device implantation experience the patient's arrhythmia requires.
From pre-travel record review and medical visa coordination, through accommodation near the treating hospital and discharge documentation for ongoing antiarrhythmic medication and device follow-up at home, Karetrip manages the complete international patient journey for arrhythmias symptoms and treatment in India.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward expert arrhythmia assessment at India's leading electrophysiology centres.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Cardiac arrhythmias require individualized evaluation by a qualified electrophysiologist or cardiologist. Stated costs and treatment outcomes are approximate estimates and may vary by patient condition and hospital. Karetrip provides medical travel coordination and logistics support; all clinical assessments, surgical procedures, and device implantations are performed independently by accredited hospital partners and certified medical specialists.